ATYR-1940 clinical trials
Also written ATYR1940.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses ATYR-1940 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ATYR1940
- 5
Studies by the year they started
5 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
aTyr Pharma, Inc. (5)
Studies
Open first, then newest update. How each study uses ATYR-1940 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)CompletedPhase 1/2aTyr Pharma, Inc.NCT02836418Written as ATYR1940
- Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular DystrophyCompletedPhase 1/2aTyr Pharma, Inc.NCT02603562Written as ATYR1940
- Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)CompletedPhase 1/2aTyr Pharma, Inc.NCT02579239Written as ATYR1940
- Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study ExtensionCompletedPhase 1/2aTyr Pharma, Inc.NCT02531217Written as ATYR1940
- Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular DystrophyCompletedPhase 1/2aTyr Pharma, Inc.NCT02239224Written as ATYR1940